Cell and Gene Therapy World, organized by Phacilitate, is taking place this coming week. After multiple years in Washington, DC, the conference has moved to Miami, Florida, where from January 17 – 20, 2017 delegates will be able to interact with over 350 companies discussing the latest advances in the commercialization of cell and gene therapies.
The entire agenda can be accessed here.
Akron will attend and participate at Cell and Gene Therapy World through a number of panels, talks and our in-person booth.
Please stop by booth #114 to meet us and learn about our latest discoveries, products and technologies. We will be there for the entire duration of the conference, and welcome anyone to interact and see the innovations we will be presenting.
Panels and Talks
Akron will participate in a number of panels and talks.
Dr. Claudia Zylberberg, Akron’s CEO, will participate in the panel Examining the cutting edge in game-changing cryoformulation, cryopreservation, thawing and storage technologies and techniques in action. The panel takes place on January 18, 2017 at 12:45 – 1:30.
Dr. Sandro Matosevic, Senior Director of Research and Development, will present during the session titled Clinical vs. commercial logistics: preparing for and navigating the transition from clinical to commercial scale. The session is scheduled to take place between 4:45 – 6:00 PM on Wednesday, January 18, 2017. The session will include presentations, a panel discussion and an audience Q&A.
Alongside public appearances, Akron will be available to meet, on a one-on-one basis, any party interested in discussing potential collaborations, partnerships or any of our products or technologies. Please contact us directly.
We hope to see you at Cell & Gene Therapy World!
Organoids – miniature organs produced via stem cells which show three-dimensional, tissue-like arrangement – enable, through physiologically-relevant environments, the study of various pathologies which these structures are assembled for. Typically assembled devoid of scaffolds, organoids have been used for both drug discovery and as three-dimensional tissue engineered constructs. As tissue engineered assemblies, organoids have originally been formed on the basis of cultured stem cells, such as induced pluripotent stem cells, which rearrange, through spatially-restricted lineage committment, into layered structures.
In the last few years, studies have highlighted that organoids can be enhanced with the introduction of substrates to which cells adhere.
In 2016, a manuscript by Dr. Timothy O’Brien from the Stem Cell Institute at the University of Minnesota described the generation of cerebral organoids from human pluripotent stem cells with the support of a chemically defined hydrogel. They managed to achieve protein expression representative of forebrain, midbrain, and hindbrain development. The manuscript was published in Stem Cells Translational Medicine.
This was demonstrated again last week, when a new study appeared which described the development of scaffold-support human lung organoids. Authored by lab of Dr. Jason Spence at the University of Michigan Medical School, the manuscript, titled A bioengineered niche promotes in vivo engraftment and maturation of pluripotent stem cell derived human lung organoids, presented the development of microporous poly(lactide-co-glycolide) (PLG) scaffolds as substrated onto which human pluripotent stem cell-based organoids developed into maturate of lung epithelial tissue.
Upon transplanting scaffold-grown organoid tissue, airway-like epithelial tissue was observed. This was attributed to the enhanced support provided by the polymer-based support scaffolds.
The authors argued that this study was the first demonstration of the development of hPSC-derived human lung organoids which showed robust engraftment in vivo and differentiation into an organized pseudostratified epithelium.
Organized cartilage was observed following Safranin0 stanining within the scaffold-human lung organoids following transplantation (Figure above), alongside cartilage marker SOX9, and the human mitochondrial marker huMITO. The scaffold-human lung organoid also displayed abundant vasculature within the tissue.
This manuscript, alongside previous other studies, forms a growing body of work which suggests that providing a physical environment to stem cell-based organoids, is critical in ensuring development and organization of mature tissue-like structure and function. Further developments may shed more light into the relationship between scaffold physicochemical properties and organoid-based human tissue establishment to develop more sophisticated system for organ regeneration.
If the development of genetic editing approaches to induce functional changes to cell behavior to enhance their efficacy has led to remarkable advances in gene-engineered cell therapy, the development, on the other hand, of synthetic systems for tissue engineered and regenerative medicine-based therapies has made inroads as a robust, fully-controllable bottom-up approach to cell and gene therapy. Synthethic approaches have often offered complementary tools – such as three-dimensional scaffolds – upon which to build in vivo-like biological function. an example of this are tissue engineered-scaffolds and three-dimensional substrates.
Now, microengineered structures have been developed which cross over to fully replace cellular function, rather than enhance it.
Case in point: A new study described the development of microengineered particles with cardiac cell-like function, as a type of “synthetic stem cell.”
The work was described in a manuscript published last week in Nature Communications, titled Therapeutic microparticles functionalized with biomimetic cardiac stem cell membranes and secretome by the lab of Dr. Ken Che, associate professor of molecular biomedical sciences at North Carolina State University.
Called synthetic cell-mimicking microparticles, they are made up of poly (lactic-co-glycolic acid) (PLGA) to which cardiac cell-extracted growth factors are added. This creates, effectively, a biodegradable, synthetic shell which contains beneficial growth factors that impart biological function. Such biological function was tested both in vitro and in vivo, in a mouse model with myocardial infarction. In both cases, and particularly in vivo, the microparticles exhibited cardiac cell-like function to support cardiac tissue growth.
While biological function is successfully displayed by these structures, they do not exhibit other cellular-like activity, such as division.
Further work is expected to answer more questions about the long-term potential of these structures as therapeutic vehicles, which will bring such work closer to answering questions about its potential clinical benefit.
Not much time is left before we close 2016 and enter the new year. As we wrap up the final few weeks of this year, we want to take the time-as we do every year-to reflect on the year that is ending.
2016 has been, for many reasons, a year of growth, excitement and surprises — globally for the cell and gene therapy field, it will be remembered for numerous breakthroughs both scientifically as well as clinically, alongside a reinvigorated federal interest in regenerative medicine and immunotherapy.
At Akron, 2016 brought all of that, alongside innovation – in discovery, manufacturing and our involvement in national and international consortia advancing the therapeutic possibilities of regenerative medicine.
Here, we want to reflect on some of Akron’s highlight from this past year:
- In the first quarter, Akron announced acceptance of a Drug Master File for Interleukin-2 by the FDA, and invites all parties interested in referencing it in their regulatory submissions to submit a request.
- At the beginning of the year, Sen. Tommy Baldwin presented The Advancing Standards in Regenerative Medicine Act, which calls for the establishment of a Standards Coordinating Body in Regenerative Medicine and Advanced Therapies. Akron is part of the task force behind this SBC, efforts regarding which are still ongoing.
- Our industry-leading product portfolio expanded by the introduction of innovative new products: we reformulated recombinant Eryothropoietin which now has enhanced stability and activity, and launched a 5% HSA solution.
- Our research efforts resulted in the publication of a number of manuscripts. A highlight is a review on liposome systems for drug delivery, Pharmaceutical Liposomal Drug Delivery: A Review of nEW Delivery Systems and a look at the regulatory landscape, which was published in Drug Delivery.
- Akron was awarded an SBIR Phase II grant by the Department of Defense for our leading innovations in the space of DMSO-free cryopreservation.
- Akron has always maintained leading presence at International Conferences and symposia. 2016 was no different: Akron was featured at ISCT, ISSCR, TERMIS, CAR-TCR to name a few.
As 2016 draws to a close, we look forward to 2017 and wish everyone happy holidays.
Our blog will resume in two weeks, on January 1st – we hope to see you usher in the new year with us.
CRISPR/CAS9 has emerged as a flexible and effective approach for genome editing with a promise for the correction of disease-causing mutations. However, most studies have so far demonstrated CRISPR as an on/off system, with little temporal control of its activity or function. Now, new research from the University of Toronto described the discover of a number of proteins that allow to precisely do this: control the activity of CRISPR specifically and conditionally, and at defined time points.
Published in Cell, the study is titled “Naturally Occurring Off-Switches for CRISPR-Cas9” from the lab of Dr. Alan Davidson.
The authors identified naturally occurring protein inhibitors of a CRISPR-Cas9 system. A bioinformatics-based approach allowed the authors to discover three proteins that inhibit N. meningitidis type II-C CRISPR-Cas system, by interacting with NmeCas9 to function as off-switches for NmeCas9 genome editing activity.
They further showed that members of all three anti-CRISPR families bind directly to the NmeCas9/sgRNA complex and inhibit in vitro DNA cleavage. Interestingly, they displayed unrelated sequences, leading the authors to postulate that they operate under different mechanisms as well.
Evolutionarily, Cas9-associating anti-CRISPRs were postulated to prevent the acquisition of new spacers (such as viral DNA) in response to external invasions, with CRISPR having a profound effect on horizontal gene transfer. This implication has profound effects on therapeutics being developed based on CRISPR/CAS9 technology.
Therapeutically, these proteins can prevent off-target effects and are thus exciting potential therapeutic targets.
In September, the Food and Drug Administration held a public hearing on the NIH campus, wherein stakeholders – researchers, the general public and investors – were called upon to voice their opinions on the current status of stem cell-based therapies in the country.
Last week, the FDA followed this up with an opinion statement, via a paper in the New England Journal of Medicine, highlighting the FDA’s position of these therapies.
In the paper, FDA commissioner Robert Califf, alongside the Center for Biologics Evaluation and Research (CBER) Director Peter Marks and CBER Deputy Director Celia Witten urged caution. In doing so, the FDA warned against “unproven” treatments as well as those with “unsufficient data.”
The FDA claimed,
“To ensure that this emerging field fulfills its promise to patients, we must first understand its risks and benefits and develop therapeutic approaches based on sound science”
“Often, these cells (whether derived from autologous or allogeneic sources) are being used in practice on the basis of minimal clinical evidence of safety or efficacy, sometimes with the claim that they constitute revolutionary treatments for various conditions.”
They go as far as calling the lack of data “worrisome,” by adding:
“Published data derived primarily from small, uncontrolled trials plus a few well-controlled, randomized trials have not reliably demonstrated the effectiveness of stem-cell treatments even in some of the most systematically studied conditions, such as heart failure and graft-versus-host disease”
The FDA calls both autologous and allogeneic treatments concerning, albeit for different reasons.
These claims will come as a disappointment to proponents of stem cell-based therapies, particularly patients who, absence other options, were hopeful that these cures would provide the benefit other medications were not able to.
The entire paper, titled “Clarifying stem-cell therapy’s benefits and risks,” can be read here.